Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Kraus, T. Articles by Pollmächer, T. Search for Related Content PubMed Citation Articles by Kraus, T. Articles by Pollmächer, T. Other Neuroleptics

Body Weight and Leptin Plasma Levels During Treatment With Antipsychotic Drugs

OBJECTIVE: Leptin is produced by fat cells and is presumed to signal the size of the adipose tissue to the brain. The authors investigated whether antipsychotic drugs that often induce weight gain affect circulating levels of leptin. METHOD: Weight, body mass index, and leptin plasma level were measured weekly over 4 weeks in psychiatric inpatients who received clozapine (N=11), olanzapine (N=8), haloperidol (N=13), or no psychopharmacological treatment (N=12). RESULTS: In patients receiving clozapine or olanzapine, significant increases in weight, body mass index, and leptin level were found, whereas these measures remained stable in patients who received haloperidol or no pharmacological treatment. CONCLUSIONS: Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization.

This article has been cited by other articles:

				O. Sentissi, J. Epelbaum, J.-P. Olie, and M.-F. Poirier Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review Schizophr Bull, December 28, 2007; (2007) sbm141v1. [Abstract] [Full Text] [PDF]

				H. Hosojima, T. Togo, T. Odawara, K. Hasegawa, S. Miura, Y. Kato, A. Kanai, A. Kase, H. Uchikado, and Y. Hirayasu Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia J Psychopharmacol, January 1, 2006; 20(1): 75 - 79. [Abstract] [PDF]

				S. Tighe and T. Dinan An overview of the central control of weight regulation and the effect of antipsychotic medication J Psychopharmacol, November 1, 2005; 19(6_suppl): 36 - 46. [Abstract] [PDF]

				E K. Hester and M. R Thrower Current Options in the Management of Olanzapine-Associated Weight Gain Ann. Pharmacother., February 1, 2005; 39(2): 302 - 310. [Abstract] [Full Text] [PDF]

				K. A. Graham, D. O. Perkins, L. J. Edwards, R. C. Barrier Jr., J. A. Lieberman, and J. B. Harp Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis Am J Psychiatry, January 1, 2005; 162(1): 118 - 123. [Abstract] [Full Text] [PDF]

				P. S. Chen, Y. K. Yang, T. L. Yeh, Y. C. Lo, and Y. T. Wang Nonketotic hyperosmolar syndrome from olanzapine, lithium, and valproic acid cotreatment Ann. Pharmacother., June 1, 2003; 37(6): 919 - 920. [Full Text] [PDF]

				M. E.J. Lean and F.-G. Pajonk Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes Diabetes Care, May 1, 2003; 26(5): 1597 - 1605. [Abstract] [Full Text] [PDF]

				J. W. Newcomer, D. W. Haupt, R. Fucetola, A. K. Melson, J. A. Schweiger, B. P. Cooper, and G. Selke Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia Arch Gen Psychiatry, April 1, 2002; 59(4): 337 - 345. [Abstract] [Full Text] [PDF]

				U. Eder, B. Mangweth, C. Ebenbichler, E. Weiss, A. Hofer, M. Hummer, G. Kemmler, M. Lechleitner, and W. W. Fleischhacker Association of Olanzapine-Induced Weight Gain With an Increase in Body Fat Am J Psychiatry, October 1, 2001; 158(10): 1719 - 1722. [Abstract] [Full Text] [PDF]

				A. HERRAN, M. T. GARCIA-UNZUETA, J. A. AMADO, M. T. DE LA MAZA, C. ALVAREZ, and J. L. VAZQUEZ-BARQUERO Effects of long-term treatment with antipsychotics on serum leptin levels The British Journal of Psychiatry, July 1, 2001; 179(1): 59 - 62. [Abstract] [Full Text] [PDF]

				L. E. Goldstein, J. Sporn, S. Brown, H. Kim, J. Finkelstein, G. K. Gaffey, G. Sachs, and T. A. Stern New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated With Olanzapine Treatment Psychosomatics, October 1, 1999; 40(5): 438 - 443. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us